Vigil Neuroscience (NASDAQ:VIGL) Receives “Market Outperform” Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research report released on Tuesday,Benzinga reports. JMP Securities currently has a $22.00 price target on the stock.

Several other research firms have also recently commented on VIGL. Guggenheim reduced their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. Wedbush increased their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $2.20 on Tuesday. The business has a 50 day simple moving average of $3.46 and a 200-day simple moving average of $3.66. Vigil Neuroscience has a 12 month low of $2.08 and a 12 month high of $6.06. The stock has a market capitalization of $89.94 million, a PE ratio of -1.07 and a beta of 1.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Vigil Neuroscience by 11.9% during the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Vigil Neuroscience during the second quarter worth $26,000. Renaissance Technologies LLC boosted its position in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after purchasing an additional 166,442 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vigil Neuroscience in the second quarter valued at $87,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.